Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.The stand-alone system,
Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.
The stand-alone system, called RapidScreen RS-2000, uses image processing and feature extraction technology originally employed in the analysis of satellite remote-sensing images. It analyzes regions of interest that may have features associated with solitary pulmonary nodules.
The proprietary algorithms are based on a combination of image processing, neural network, and fuzzy logic techniques developed from a database of thousands of chest films of early-stage lung cancer and cancer-free cases.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.